Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma.
BACKGROUND
The results of a recent study suggested that ultraviolet A1 radiation (UVA1R; 340-400 nm) phototherapy for atopic dermatitis works through induction of apoptosis in skin-infiltrating helper T cells, indicating the possibility that other helper T cell-mediated skin diseases may respond to UVA1R as well.


OBJECTIVE
The purpose of this open pilot study was to assess the therapeutic effectiveness of UVA1 phototherapy for cutaneous T-cell lymphoma (CTCL).


METHODS
UVA1 phototherapy was used as monotherapy in patients (n = 3) with histologically proven CTCL (stages IA and IB). For daily whole body UVA1 irradiations, either a high-dose (n = 2; 130 J/cm2 UVA1 per exposure) or medium-dose (n = 1; 60 J/cm2 UVA1) regimen was used. Therapeutic effectiveness was assessed clinically and histologically.


RESULTS
In each of the 3 patients, skin lesions began to resolve after only a few UVA1 radiation exposures. Complete clearance was observed between 16 and 20 exposures, regardless of whether the high- or medium-dose regimen had been employed.


CONCLUSIONS
These studies suggest that patients with CTCL stages IA and IB can be treated effectively with UVA1 phototherapy.
Department of Dermatology, Heinrich-Heine-University, Düsseldorf, Germany.
H
H
Plettenberg
H
H
Stege
M
M
Megahed
T
T
Ruzicka
Y
Y
Hosokawa
T
T
Tsuji
A
A
Morita
J
J
Krutmann
D000368:Aged; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000532:radiotherapy*; D014467:Ultraviolet Therapy